- Home
- CISS vs CMND Comparison
CISS vs CMND Comparison
Compare CISS & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | CMND |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CISS | CMND |
|---|---|---|
| Price | $0.54 | $6.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 428.5K | 24.8K |
| Earning Date | 11-17-2026 | 09-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.07 |
| 52 Week High | $6.06 | $7.16 |
Technical Indicators
Market Signals| Indicator | CISS | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 66.02 |
| Support Level | $0.41 | $0.66 |
| Resistance Level | $0.61 | $7.16 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 25.47 | 0.00 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.